Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies Oct 16, 2023 7:00 am EDT
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference Oct 2, 2023 7:00 am EDT
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update Sep 6, 2023 7:01 am EDT
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement Sep 6, 2023 7:00 am EDT
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study Jun 26, 2023 7:00 am EDT
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical May 31, 2023 7:00 am EDT
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones May 30, 2023 7:00 am EDT